Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 3 sources
Summary
The proposed population comprises adults previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with prior anti-EGFR therapy for RAS wild-type disease. The pivotal regimen combines daily oral zanzalintinib with intravenous atezolizumab every three weeks. This is an investigational treatment position, not an approved prescribing recommendation or established commercial access pathway.